Research Output

2023 2023 2022 2022 2021 2021 0.0 0.0 0.2 0.2 0.4 0.4 0.6 0.6 0.8 0.8 1.0 1.0 1.2 1.2 1.4 1.4 1.6 1.6 1.8 1.8 2.0 2.0
Now showing 1 - 5 of 5
No Thumbnail Available
Publication

Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile

2022 , Alejandro Jara , Eduardo A. Undurraga , José R. Zubizarreta , Cecilia González , ACEVEDO ROMO, JOHANNA PATRICIA , Alejandra Pizarro , Verónica Vergara , Mario Soto-Marchant , Rosario Gilabert , Juan Carlos Flores , Pamela Suárez , Paulina Leighton , Pablo Eguiguren , Juan Carlos Ríos , Jorge Fernandez , Heriberto García-Escorza , ARAOS BRALIC, RAFAEL IGNACIO

AbstractThe outbreak of the B.1.1.529 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Omicron) has caused an unprecedented number of Coronavirus Disease 2019 (COVID-19) cases, including pediatric hospital admissions. Policymakers urgently need evidence of vaccine effectiveness in children to balance the costs and benefits of vaccination campaigns, but, to date, the evidence is sparse. Leveraging a population-based cohort in Chile of 490,694 children aged 3–5 years, we estimated the effectiveness of administering a two-dose schedule, 28 days apart, of Sinovac’s inactivated SARS-CoV-2 vaccine (CoronaVac). We used inverse probability-weighted survival regression models to estimate hazard ratios of symptomatic COVID-19, hospitalization and admission to an intensive care unit (ICU) for children with complete immunization over non-vaccination, accounting for time-varying vaccination exposure and relevant confounders. The study was conducted between 6 December 2021 and 26 February 2022, during the Omicron outbreak in Chile. The estimated vaccine effectiveness was 38.2% (95% confidence interval (CI), 36.5–39.9) against symptomatic COVID-19, 64.6% (95% CI, 49.6–75.2) against hospitalization and 69.0% (95% CI, 18.6–88.2) against ICU admission. The effectiveness against symptomatic COVID-19 was modest; however, protection against severe disease was high. These results support vaccination of children aged 3–5 years to prevent severe illness and associated complications and highlight the importance of maintaining layered protections against SARS-CoV-2 infection.

No Thumbnail Available
Publication

Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study

2023 , Alejandro Jara , Eduardo A. Undurraga , Juan Carlos Flores , José R. Zubizarreta , Cecilia González , Alejandra Pizarro , Duniel Ortuño-Borroto , ACEVEDO ROMO, JOHANNA PATRICIA , Katherinne Leo , Fabio Paredes , Tomás Bralic , Verónica Vergara , Francisco Leon , Ignacio Parot , Paulina Leighton , Pamela Suárez , Juan Carlos Rios , Heriberto García-Escorza , ARAOS BRALIC, RAFAEL IGNACIO

No Thumbnail Available
Publication

Navigating economic turmoil: Chilean businesses during COVID-19 lockdowns and vaccine rollouts

2023 , Julio A. Pertuze , José Pablo Montégu , Cecilia González , Rafael Araos , Paula Daza

No Thumbnail Available
Publication

Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study

2022 , Alejandro Jara , Eduardo A Undurraga , José R Zubizarreta , Cecilia González , Alejandra Pizarro , Johanna Acevedo , Katherinne Leo , Fabio Paredes , Tomás Bralic , Verónica Vergara , Marcelo Mosso , Francisco Leon , Ignacio Parot , Paulina Leighton , Pamela Suárez , Juan Carlos Rios , Heriberto García-Escorza , ARAOS BRALIC, RAFAEL IGNACIO

No Thumbnail Available
Publication

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

2021 , Alejandro Jara , Eduardo A. Undurraga , Cecilia González , Fabio Paredes , Tomás Fontecilla , Gonzalo Jara , Alejandra Pizarro , ACEVEDO ROMO, JOHANNA PATRICIA , Katherinne Leo , Francisco Leon , Carlos Sans , Paulina Leighton , Pamela Suárez , Heriberto García-Escorza , ARAOS BRALIC, RAFAEL IGNACIO